ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2129

Dickkopf-1 Is Increased in Rheumatoid Arthritis of Recent Onset and Might Be a New Biomarker of Structural Progression. Data From the Espoir Cohort

Raphaèle Seror1, Stephan Pavy2, Thierry Schaeverbeke3, Alain Saraux4, Xavier Mariette5 and Corinne Miceli-Richard1, 1Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, 2Hopital Bicetre, Paris, France, 3Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 4Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, 5Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Dickkopf-1 (DKK-1) is an inhibitory protein of the Wnt signalling pathway that could be involved in subchondral bone erosions occurring in rheumatoid arthritis (RA). Few studies have investigated the role of DKK1 in RA. We aimed to investigate DKK-1 serum levels in patients with recent inflammatory arthritis fulfilling ACR/EULAR criteria for RA and to investigate the parameters associated with DKK-1 increase and the relationship between DKK-1 levels and radiographic changes in RA.

Methods:

The ESPOIR cohort is a prospective, multicenter French cohort of patients with early arthritis, including 813 patients between 2002 and 2008. DKK-1 serum levels were assessed at baseline on the whole cohort by sandwich ELISA (Biomedica, Vienna). DDK-1 serum levels were further analyzed at inclusion in the subgroup of patients fulfilling ACR/EULAR criteria for RA after 2 years of follow-up (N=694; 85.3%) and compared with serum levels from 70 age and sex-matched controls (without autoimmune or chronic inflammatory disease). Uni and multivariate analyses were conducted to look for parameters associated or correlated with DKK-1 serum levels. DKK-1 serum levels were also compared between patients with and without radiographic change at baseline and after 2 years of follow-up.

Results:

Among the 813 patients with early arthritis, 694 of them (85%) fulfilled ACR/EULAR criteria for RA (mean age 48.5±12.3, 78.2% female, with mean baseline DAS28=5.3±1.2, 54.6% anti-CCP positive). Serum DKK-1 level was significantly increased in RA patients compared to healthy controls (28.0±13.2 vs 10.8±9.3; p<0.0001). In univariate analysis, the level of DDK-1 was significantly correlated with the level of CRP (r=0.16; p<0.0001), ESR (r=0.11; p=0.005), patient global assessment (PGA) (r=0.08; p=0.046) and DAS28 (r=0.09; p=0.02). In addition, we found that DKK-1 level was significantly higher in patients with typical erosion related to RA at baseline, compared to those without (32.4±14.0 vs 27.2±12.9; p=0.0001). In the multivariate analysis adjusted for DAS28, PGA, and smoking status, only CRP levels and the presence of typical erosions related to RA remained associated with DKK-1 levels. Last, the most interesting result was that baseline DKK-1 levels was predictive of radiological progression (defined by increase of modified Sharp score >1) (29.3±13.0 in patients with progression vs 16.7±12.1 in patients without progression; p=0.025). Nevertheless, DKK-1 was no more associated with radiological progression in a model including other main predictors of severity (erosion at baseline, and anti-CCP positivity) in the multivariate analysis.

Conclusion:

This study conducted in a large cohort of patients presenting with early onset RA clearly showed an increase in DKK-1 serum levels, associated with disease activity, biological inflammation and bone erosions at baseline. More interestingly, increase in DKK-1 serum levels were predictive of structural progression at 2 years and, then might be an interesting new structural biomarker in early RA.


Disclosure:

R. Seror,
None;

S. Pavy,
None;

T. Schaeverbeke,
None;

A. Saraux,
None;

X. Mariette,
None;

C. Miceli-Richard,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dickkopf-1-is-increased-in-rheumatoid-arthritis-of-recent-onset-and-might-be-a-new-biomarker-of-structural-progression-data-from-the-espoir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology